Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
Saved in:
| Title: | Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK. |
|---|---|
| Authors: | McCrimmon, Rory J.1 (AUTHOR) r.mccrimmon@dundee.ac.uk, Palmer, Karen2 (AUTHOR), Alsaleh, Abdul Jabbar Omar3 (AUTHOR), Lew, Elisheva4 (AUTHOR), Puttanna, Amar2,5 (AUTHOR) |
| Source: | Diabetes Therapy. Jun2022, Vol. 13 Issue 6, p1203-1214. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 18696953 |
|---|---|
| DOI: | 10.1007/s13300-022-01267-3 |
